Valence 標誌
熱門
登入

加入到自選清單
專業圖表

Latigo Biotherapeutics In...

NasdaqGS: LTGO · 即時價格 · USD
19.49
-0.57 (-2.84%)
收盤時： Aug 14, 2026, 3:59 PM
19.49
+0.00%
盤後: 7:34 PM

Latigo Biotherapeutics Inc. (LTGO) Stock Price, Analysis & Data

-2.84%
買價19.1
市值1.17B
營收 (ttm)n/a
淨利（ttm）-111.18M
貝塔n/a
EPS (ttm)-2.53
本益比（ttm）n/a
正向 PEn/a
P/B (ttm)-0.46
P/S (ttm)n/a
Earnings Daten/a
賣價18.69
成交量303,580
20 日平均成交量923,940
打開20.01
上一頁關閉20.06
日間範圍18.46 - 20.10
52 週範圍17.22 - 22.47
分析師n/a
目標價n/a
股利n/a
Ex-股利日期n/a

關於LTGO

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibito...

[閱讀更多]
工業 Biotechnology
部門 Healthcare
IPO 日期 Aug 7, 2026
員工 59
證券交易所 NasdaqGS
股票代號 LTGO
網站 https://latigobio.com
完整的公司簡介

財務表現

Latigo Biotherapeutics 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。 淨利為 -109.17M，較前期增加 78.43%。

財務報表
news image

1 日 前 · 24/7 Wall St.

Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public

A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science ...

news image

5 天 前 · Simply Wall St.

Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued

Latigo Biotherapeutics (LTGO) recently raised US$345.6 million in its IPO, offering 19,200,000 common shares at US$18 each, following publication in the New England Journal of Medicine of clinical dat...